Tivic Health Systems (TIVC) Investor presentation summary

Strategic focus and assets

• Developing late-stage, de-risked biologic assets targeting radiation damage, oncology, and immune system modification.

• Portfolio includes Entolimod (late Phase III) and Entolasta (pre-clinical), both TLR5 agonists with exclusive worldwide rights secured in 2025.

• Over $140M invested, with 40+ human and animal studies and 60+ patents and patents pending.

• Integrated manufacturing capabilities and a subsidiary CDMO, Velocity Bioworks, to accelerate clinical timelines and create new revenue streams.

• Experienced management team with approximately 50 employees.

Clinical pipeline and development

• Entolimod targets acute radiation syndrome (ARS), acute neutropenia, thrombocytopenia, immunosenescence, and general mucositis, with multiple programs in late-stage clinical development.

• Entolasta is in pre-clinical development for chronic radiation syndrome and related indications.

• Clinical pipeline spans discovery through Phase III, with several investigator-led study opportunities.

• Demonstrated unique therapeutic value, including a 3x increase in survival rate for ARS.

Market opportunity and competitive landscape

• Global market for G-CSF and biosimilars is $9.46B in 2024, projected to reach $21.3B by 2032 (10.7% CAGR).

• Entolimod offers a new class of therapy with both hemopoietic and GI tract protection, differentiating from current SOC (G-CSF drugs).

• US government agencies have funded development and are lead customer opportunities; international stockpile opportunities exist.

• Competitive landscape includes Neupogen, Neulasta, Nplate, and Leukine, but Entolimod provides broader therapeutic, prophylactic, and regenerative benefits.